You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NSCLC

Showing 1 - 25 of 5,404
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Single Cell Mutations inPanel of Known Oncogenes in NSCLC

Recruiting
  • NSCLC
  • Tapestry technology
  • Monza, MB, Italy
    Fondazione IRCCS San Gerardo dei Tintori
Sep 15, 2023

Clinical Implications for NSCLC Patients With Rare Mutations

Recruiting
  • NSCLC
  • +2 more
    • Shanghai, Shanghai, China
    • +1 more
    Jan 18, 2023

    NSCLC Associated With Leptomeningeal Metastases Trial (Tislelizumab, pemetrexed)

    Not yet recruiting
    • NSCLC Associated With Leptomeningeal Metastases
    • Tislelizumab, pemetrexed
    • (no location specified)
    Nov 21, 2023

    NSCLC Stage IV, ALK Fusion Protein Expression Trial (Peptide vaccine)

    Not yet recruiting
    • NSCLC Stage IV
    • ALK Fusion Protein Expression
    • Peptide vaccine
    • (no location specified)
    Jul 21, 2023

    NSCLC Trial in Nanjing (NK510, Tislelizumab,atezolizumab or sugemalimab)

    Recruiting
    • NSCLC
    • NK510
    • Tislelizumab，atezolizumab or sugemalimab
    • Nanjing, Jiangsu, China
      General Hospital of Eastern Theater Command
    Oct 23, 2023

    Stage IV NSCLC Trial in Houston (Poly ICLC, IVIG)

    Not yet recruiting
    • Stage IV NSCLC
    • Houston, Texas
      Michael E. DeBakey VA Medical Center, Houston, TX
    Sep 28, 2023

    NSCLC Trial in Shanghai (IN10018, Furmonertinib)

    Recruiting
    • NSCLC
    • Shanghai, China
      Shanghai Pulmonary Hospital
    Aug 8, 2023

    NSCLC Trial in Singapore (Afatinib 40 MG)

    Not yet recruiting
    • NSCLC
    • Afatinib 40 MG
    • Singapore, Singapore
      National University Hospital
    Sep 25, 2023

    NSCLC Trial in Guangzhou (Neratinib tablets)

    Not yet recruiting
    • NSCLC
    • Neratinib tablets
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 1, 2023

    NSCLC Trial in Changsha (BEBT-109)

    Completed
    • NSCLC
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Aug 20, 2023

    NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

    Not yet recruiting
    • NSCLC
    • +2 more
    • Guangzhou, Guangdong, China
      Cancer Center of Sun-Yat Sen University
    Sep 19, 2023

    NSCLC Trial (Atezolizumab, Tiragolumab)

    Not yet recruiting
    • NSCLC
    • (no location specified)
    Apr 5, 2023

    Aspirin in Combination With Trametinib and Dabrafenib

    Not yet recruiting
    • NSCLC
    • +4 more
    • Combind asprin with Trametinib and Dabrafenib
    • (no location specified)
    Aug 4, 2023

    NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • MK-2870
    • +2 more
    • (no location specified)
    Oct 3, 2023

    Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

    Recruiting
    • Non-small Cell Lung Cancer
      • Guanzhou, China
        Sun Yat-sen University Cancer Center
      Aug 11, 2023

      Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - NSCLC Trial in Kansas City, Overland Park, Lee's Summit (Cabozantinib,

      Not yet recruiting
      • Lung Cancer
      • +3 more
      • Kansas City, Kansas
      • +3 more
      May 12, 2023

      NSCLC Trial (99mTc-H7ND SPECT/CT imaging performed)

      Not yet recruiting
      • NSCLC
      • 99mTc-H7ND SPECT/CT imaging performed
      • (no location specified)
      Aug 17, 2023

      Lung Cancer Stage III Trial (ctDNA)

      Not yet recruiting
      • Lung Cancer Stage III
      • ctDNA
      • (no location specified)
      Oct 26, 2023

      NSCLC, EGFR Gene Mutation Trial in Nanjing (neo-antigen vaccine)

      Recruiting
      • NSCLC
      • EGFR Gene Mutation
      • neo-antigen vaccine
      • Nanjing, China
        The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,
      Oct 19, 2023

      Response Rate in Patients With Advanced NSCLC on ICI

      Recruiting
      • Non Small Cell Lung Cancer Metastatic
      • Diabetes Mellitus
      • Pembrolizumab
      • Assiut, Egypt
        Assiut university
      Oct 20, 2023

      Non Small Cell Lung Cancer Trial in Brussels (FAPI PET/CT)

      Recruiting
      • Non Small Cell Lung Cancer
      • FAPI PET/CT
      • Brussels, Belgium
        Institut Jules Bordet
      Oct 24, 2023

      Non Small Cell Lung Cancer, EGFR Gene Mutation, Immune Checkpoint Inhibitor Trial in Jerusalem (concomitant TTFields treatment

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • +2 more
      • concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment
      • concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment
      • Jerusalem, Israel
        Shaare Zedek Medical Center
      Jan 22, 2023

      NSCLC Trial in Shanghai (Toripalimab, Cryoablation)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • Shanghai, Shanghai, China
        Shanghai Chest Hospital
      Nov 7, 2023

      NSCLC Trial (Dupilumab, Cemiplimab)

      Not yet recruiting
      • Non-Small Cell Lung Cancer
      • Dupilumab
      • Cemiplimab
      • (no location specified)
      Oct 12, 2023

      NSCLC, Stage III Trial in Beijing (Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC),

      Recruiting
      • NSCLC, Stage III
      • Beijing, Beijing, China
        Beijing Tsinghua Chang Gung Hospital
      Nov 4, 2022